{"schema_version":"secwatch.filing_event.v1","accession":"0001581280-25-000006","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.413034+00:00","generated_at":"2026-05-17T21:27:14.924329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M","bullets":["Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.","Gross margin improved to 53.4% from 43.3% YoY; net income $20.4M ($0.34/share) vs loss $85.6M.","FY2025 revenue guidance raised to $374-376M; gross margin guidance raised to 50.5%-51%.","Adjusted EBITDA loss narrowed to $(8.0)M from $(22.0)M; expect breakeven by end of FY2026.","Added ~184 net new customers; shipped 237,000 genes, up 12% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001581280-25-000006","json":"https://secwatch.observer/filing/0001581280-25-000006.json","markdown":"https://secwatch.observer/filing/0001581280-25-000006.md","text":"https://secwatch.observer/filing/0001581280-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000158128025000006/0001581280-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000158128025000006/twist-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:27:14.924329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}